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ABSTRACT
microRNA-29b (miR-29b) is known to be associated with TGF-β-mediated 
fibrosis, but the mechanistic action of miR-29b in liver fibrosis remains unclear and is 
warranted for investigation. We found that miR-29b was significantly downregulated 
in human and mice fibrotic liver tissues and in primary activated HSCs. miR-29b 
downregulation was directly mediated by Smad3 through binding to the promoter of 
miR-29b in hepatic stellate cell (HSC) line LX1, whilst miR-29b could in turn suppress 
Smad3 expression. miR-29b transduction in the liver of mice prevented CCl4 induced-
fibrogenesis, concomitant with decreased expression of α-SMA, collagen I and TIMP-1. 
Ectopic expression of miR-29b in activated HSCs (LX-1, HSC-T6) inhibited cell viability 
and colony formation, and caused cell cycle arrest in G1 phase by downregulating 
cyclin D1 and p21cip1. Further, miR-29b induced apoptosis in HSCs mediated by 
caspase-9 and PARP. miR-29b inhibited its downstream effectors of PIK3R1 and AKT3 
through direct targeting their 3’UTR regions. Moreover, knockdown of PIK3R1 or AKT3 
suppressed α-SMA and collagen I and induced apoptosis in both HSCs and in mice. 
In conclusion, miR-29b prevents liver fibrogenesis by inhibiting HSC activation and 
inducing HSC apoptosis through inhibiting PI3K/AKT pathway. These results provide 
novel mechanistic insights for the anti-fibrotic effect of miR-29b. 
INTRODUCTION
Hepatic fibrosis is an integral part in the progression 
of chronic inflammatory liver disease featured with the 
excessive accumulation of extracellular matrix (ECM) 
proteins. With prolonged liver damage, fibrosis may 
progress to cirrhosis and primary liver cancer [1]. Unlike 
the irreversible cirrhosis, hepatic fibrosis is a reversible 
disease, and an effective treatment can be able to prevent 
or reverse the fibrotic process [2]. Hepatic stellate cells 
(HSCs) play a key role in liver fibrogenesis [3]. HSCs 
are quiescent in normal liver but will be activated in 
response to liver damage [4]. Activated HSCs, on one 
side, secrete transforming growth factor beta-1 (TGF- 
β1), the most potent fibrogenetic factor, to induce collagen 
production and ECM accumulation [5,6]; on the other 
side, activated HSCs inhibit the activation of matrix 
metalloproteinases (MMPs) by up-regulation of tissue 
inhibitors of metalloproteinases (TIMPs), and cause 
reduction of matrix degradation [7,8]. This imbalance 
between ECM degradation and accumulation results in 
occurrence of liver fibrosis. Therefore, controlling the 
activation of HSCs is considered as a promising therapy 
to antagonize liver fibrosis. There is a decrease in the 
number of activated HSCs when fibrosis resolves. The fate 
of the activated HSCs is either returning to a quiescent 
state, or undergoing apoptosis [9]. There is pressing need 
for effective molecular targeted therapies for liver fibrosis 
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through regulating HSCs activation.
microRNAs (miRNAs) are endogenous small 
non-coding RNAs that control gene expression by 
degrading target mRNA or suppressing their translation 
at the 3’-untranslated regions (3’-UTR). miRNAs play 
fundamental roles in a variety of cellular processes 
including cell differentiation and proliferation [10]. 
Aberrant expression of miRNA is reported to be associated 
with the liver diseases including viral hepatitis [11], fatty 
liver disease [12] and liver cancer [13]. It is reported 
recently that miRNAs can regulate the activation of HSCs 
and thereby regulate liver fibrosis [14]. Identification of 
key abnormally expressed miRNA in pathologic state will 
be helpful to further understand the disease mechanism, 
and modulation of its activity may be of therapeutic 
benefit. We have recently reported that miR-29b, a 
negative regulator for the Smad3 and type I collagen is a 
key regulator in renal fibrosis [15] and pulmonary fibrosis 
[16]. However, the biological role of miR-29b in liver 
fibrosis and its possible contribution acting as a protective 
factor against liver fibrogenesis remain largely unclear. In 
this study, we first determined whether aberrant expression 
of miR-29b exists in liver fibrosis, and found that miR-
29b was significantly downregulated in fibrotic liver 
tissues from human and rodent model, and in activated 
HSCs. The functional role and therapeutic potential for 
miR-29b in liver fibrogenesis were therefore characterized 
in vivo using an ultrasound-microbubble-mediated miR-
29b transfer, and in vitro by overexpression of miR-29b 
in HSCs. We revealed that miR-29b prevents hepatic 
fibrogenesis in mice by attenuating HSCs activation and 
inducing HSCs apoptosis. In particular, we demonstrated 
by a variety of in vitro and in vivo approaches that 
phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) 
and protein kinase B (AKT3) are direct targets of miR-
29b in HSCs responsible for signaling onset of HSCs 
activation and liver fibrosis.
RESULTS
miR-29b is down-regulated in human fibrotic liver 
tissues
We first assessed the expression of miR-29b in 20 
human liver fibrosis tissues and 13 normal human liver 
biopsies. As determined by real-time PCR, miR-29b 
expression level was significantly lower in fibrotic tissues 
comparing to the normal liver tissues (P = 0.002) (Figure 
1A).
miR-29b is expressed in primary quiescent HSCs, 
but down-regulated in activated HSCs 
Freshly isolated rat HSCs retained their quiescent 
phenotype with distinct stellate morphology when 
cultured on plastic for 1-2 days (Figure 1B). They became 
fully activated after cultured for more than 7 days with 
the typical cell morphology of a large, spread out and 
flattened polygonal shape observed at day 21 day (Figure 
1B). mRNA expression of the key genes involved in the 
activation of HSCs including α-SMA, discoidin domain 
receptor 2 (DDR2), fibronectin 1 (FN1), integrin â1 
(ITGB1) and platelet-derived growth factor receptor-β 
(PDGFR-β) was up-regulated in day 21 HSCs as compared 
to day 2 HSCs (Figure 1C), confirming the activation 
status of day 21 HSCs from the primary culture. We found 
that miR-29b was abundant in quiescent HSCs, but was 
significantly decreased in activated HSCs (Figure 1D).
Down-regulation of miR-29b is mediated by 
Smad3 
We have previously reported that miR-29b is a 
downstream target gene of Smad3 and it is negatively 
regulated by TGF-β/Smad signaling in renal fibrosis [15]. 
We evaluated whether the downregulation of miR-29b in 
liver fibrosis was mediated by Smad3 and their potential 
interaction. Human HSC cell line LX1 was treated with 
TGF-β1 (2 ng/ml) for 0, 3h, 6h, 12h and 24h, respectively. 
Protein expression of phosphorylated-Smad3 (p-Smad3) 
and α-SMA was increased in a time dependent manner 
(Figure 1E). However, the miR-29b expression showed a 
time-dependent decrease by TGF-β1 in LX1 cells (Figure 
1F), indicating that miR-29b is a potential downstream 
target of TGF-β/Smad3 signaling. 
We further determined the interaction between 
Smad3 and miR-29b. We have previously reported that 
a Smad response element (TGTCAGTCT) is located at 
~22kb upstream of miR-29b, a highly conserved region 
[15]. By chromatin immunoprecipitation (ChIP)-PCR 
assay, we revealed the directly binding of Smad3 to miR-
29b promoter in LX1 cells with TGF-β1 treatment (Figure 
1G), indicating that miR-29b is a direct transcriptional 
target of Smad3 in HSCs.
miR-29b prevents carbon tetrachloride (CCl4)-
induced liver fibrosis in mice 
We next examined whether introduction of miR-
29b by gene transfer could ameliorate CCl
4
-induced 
liver fibrosis in vivo. The Doxycycline-inducible miR-
29b expressing plasmids (pTRE2-miR-29b/pTet-on) 
were transfected into the liver through tail vein injection 
followed by ultrasound treatment transcutaneously at the 
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liver location (Figure 2A). In our pilot study, the efficacy 
of miR-29b delivery to the liver in mice was detected 
by real-time PCR and consistent miR-29b expression 
was detected at week 1 and week 2 (Figure 2B). In this 
connection, a tail vein injection was given for 3 times in 8 
weeks duration in mice treated with CCl
4
. Over-expression 
of miR-29b was confirmed in miR-29b-transfected mice 
in the liver by real-time RT-PCR (Figure 2C) and by miR-
29b in situ hybridization (Figure 2D). 
As shown in Figure 3A, significant bridging fibrosis, 
fibrous septa and cirrhotic nodules were observed in liver 
sections in mice treated with CCl
4
 and transduced with 
control vector for 8 weeks by Picrosirius red-staining; 
whilst, transduction of miR-29b caused marked reduction 
in the distribution of collagen fibers. Morphometric 
analysis yielded concordant results where the Picrosirius 
red-stained collagen areas were significantly reduced in 
miR-29b introduced mice compared to the control vector 
transfected mice (P < 0.05) (Figure 3B). Moreover, 
quantitation of collagen by measuring the amount of 
hepatic hydroxyproline content supported the significant 
improvement of liver fibrosis by miR-29b delivery (P < 
0.01) (Figure 3C). 
Figure 1: miR-29b is downregulated in liver fibrosis and in activated hepatic stellate cells (HSCs) and down-regulation 
of miR-29b is mediated by Smad3. (A) Level of miR-29b was significantly lower in human fibrotic liver tissues (n = 20) than in normal 
liver tissues (n = 13). (B) Representative morphological images of primary cultured quiescent HSCs and activated HSCs of rat origin. (C) 
mRNA expression of key genes involved in the activation of HSCs including α-SMA, DDR2, FN1, ITGB1 and PDGFRb were analyzed by 
real-time PCR. (D) miR-29b expression is reduced in activated HSCs compred to the quiescent HSCs. (E) Human HSC cell line LX1 was 
treated with TGF-β1 (2 ng/ml) for 0, 3h, 6h, 12h and 24h, respectively. Protein expression of phosphorylated-Smad3 (p-Smad3) and α-SMA 
was determined by Westerb blot, GAPDH was used as loading control. (F) miR-29b expression was examined by real-time RT-PCR. (G) 
DNA sequence alignments indicate a highly conserved Smad3 binding site at the promoter region 22kb upstream of miR-29b in difference 
species (upper panel). Functional interaction between Smad3 and miR-29b promoter was evaluated by Chromatin Immunoprecipitation 
(ChIP)-PCR. LX1 cells were treated with TGF-β1 (2ng/ml) for 24 h, then cross-linked with formaldehyde and lysed. The soluble chromatin 
was immunoprecipitated with the anti-Smad3 Ab. Two pairs of primers were designed to detect the Smad3-containing promoter region of 
miR-29b by ChIP-PCR (lower panel) and a direct interaction be Smad3 and miR-29b was demonstrated.
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Figure 2: Ultrasound-mediated gene transfer of miR-29b in CCl
4
-induced liver fibrosis in C57BL6 mice. (A) C57/BL6 
mice were administered CCl
4 
twice per week by Intraperitoneal injection for 8 weeks to induce liver fibrosis. Separately, CCl
4 
treated mice 
were introduced with miR-29b using pTRE2-miR-29b-Tet-on plasmid or control vector by tail vein injection, followed by 5 min ultrasound 
treatment (2W/cm2) transcutaneously on liver location as described in Materials and Methods. (B) The efficacy of miR-29b delivery to the 
liver of mice was determined by quantitative real-time PCR and consistent miR-29b expression was detected at week 1 and week 2. Thus, 
a tail vein injection was given for 3 times in 8 weeks duration in mice treated with CCl
4
. (C) Over-expression of miR-29b was confirmed 
in miR-29b-transfected mice in the liver by real-time RT-PCR and (D) by in situ hybridization. 
Figure 3: Gene transfer of miR-29b prevents CCl4-induced liver fibrosis in mice. (A) Collagen deposition by Picrosirius 
red staining of liver. (B) Semi-quantitative analysis of collagen area by Picrosirius red staining. (C) The quantification of collagen in liver 
tissues of mice was displayed by content of hydroxyproline (ug/mg liver) in different treatment groups. (D) Effects of CCl
4
 and transduced 
with miR-29b on hepatic protein expression of p-Smad3, collagen I, α-SMA and TIMP-1 by Western blot. GAPDH was used as loading 
control. Values are mean ± SD, *P < 0.001 compared with control mice (treated with oil); #P < 0.01, ##P < 0.001 compared with mice 
treated with CCl
4
. (E) Proposed scheme of the mechanism by which miR-29b prevents liver fibrogenesis in mice.
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miR-29b suppresses genes involved in fibrogenesis
We examined molecular factors involved in HSC 
activation (α-SMA), collagen production (p-Smad3, 
collagen I) and matrix degradation (TIMP-1) by Western 
blot. Introduction of miR-29b significantly reduced protein 
expression of p-Smad3, collagen I, α-SMA and TIMP-1 
(Figure 3D), inferring that the anti-fibrosis effect of miR-
29b was mediated at least by suppressing genes involved 
in fibrogenesis (Figure 3E).
miR-29b reduces the activation of hepatic stellate 
cells in vitro
Given the crucial role of miR-29b in suppressing 
liver fibrosis in vivo, we examined whether miR-29b 
plays any part in modulation of the activation of HSC in 
vitro. To test this, two activated HSC cell lines (LX-1 and 
HSC-T6) were transfected with pre-miR-29b or pre-miR-
control (Figure 4A). Introduction of miR-29b resulted 
in significant down-regulation of α-SMA, DDR2, FN1, 
ITGB1 and PDGFR-β mRNAs (Figure 4B). This was 
Figure 4: miR-29b inhibits HSC proliferation and arrests cell cycle in G1 phase. (A) Ectopic expression of miR-29b in HSC 
cell lines LX1 and HSC-T6 was confirmed by RT-PCR. (B) mRNA expression of α-SMA, DDR2, FN1, ITGB1 and PDGFRb in miR-29b 
expressed HSCs and control HSCs by real-time PCR. (C) Eectopic expression of miR-29b suppressed protein expression of p-Smad3, 
α-SMA, collagen I and TIMP-1 in LX1 and HSC-T6. (D). miR-29b inhibited HSC cell growth as determined by cell viability assay, and 
(E) by colony formation assay. (F) miR-29b increased G1 phase cell population, but decreased S phase cell population as examined by 
flow cytometry analysis. (G) Protein expression of key G1 cell cycle regulators cyclinD1 and p21cip1 by Western blot. GAPDH was used as 
loading control.
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confirmed by the downregulation of protein expression 
of p-Smad3, α-SMA, collagen I and TIMP-1 (Figure 4C), 
inferring the suppressed activation of HSCs by miR-29b.
miR-29b inhibits HSCs proliferation by causing 
cell cycle arrest in G1 phase
To evaluate the effects of miR-29b on cell 
proliferation, LX-1 and HSC-T6 cells were transfected 
with either pre-miR-29b or pre-miR-control. As 
determined by cell viability assay, miR-29b significantly 
suppressed cell growth in LX-1 and HSC-T6 cells (P < 
0.001) (Figure 4D). The growth suppressive effect of 
miR-29b in HSC cells was further confirmed by a colony 
formation assay, which showed the colonies formed in 
LX1 and HSC-T6 cells transfected with miR-29b were 
significantly less than those of control cells (Figure 4E).
To determine the mechanism by which miR-29b 
inhibited HSC cells proliferation, we examined the 
effect of miR-29b on cell cycle distribution. Ectopic 
expression of miR-29b in LX1 led to a significant increase 
in the G1 phase population (P < 0.01; Figure 4F), and a 
corresponding reduction in the S phase cells (P < 0.01; 
Figure 4F). Western blot analysis revealed that miR-29b 
suppressed the G1-S transition promoter cyclin D1 and 
induced the G1 gatekeeper P21Cip1 (Figure 4G), further 
confirming the effect of miR-29b in blocking the cell cycle 
at the G1/S checkpoint.
miR-29b induces apoptosis in HSCs
In order to determine whether the observed 
suppressive effect of cell growth by miR-29b was due to 
an induction of apoptosis, cell apoptosis was evaluated by 
Annexin V/7-AAD double staining and flow cytometry. 
Ectopic expression of miR-29b in LX1 cells caused a 
significant increase of apoptotic cells (P < 0.05, Figure 
5A). Moreover, the apoptotic index quantified by 
transferase-mediated nick-end labeling (TUNEL) positive 
cells was significantly increased in LX1 transfected with 
Figure 5: miR-29b induces HSC apoptosis. (A) HSCs apoptosis was determined by Annexin V/7-AAD staining and analyzed by 
flow cytometry. Annexin V positive apoptotic cells were significantly increased in LX1 cells transfected with miR-29b compared with 
those transfected with control-miR. Data are mean ± SD from four independent experiments in duplicate. (B) Cell apoptosis in HSCs was 
examined by TUNEL staining. Apoptosis index was quantified by counting the proportion of TUNEL-positive cells. (C) Effects of miR-29b 
on protein expression of apoptosis-related genes by Western blot. GAPDH was used as loading control.
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pre-miR-29b compared with pre-miR-control (P < 0.001) 
(Figure 5B). In keeping with this, protein expression of 
the active forms of key apoptosis genes including cleaved 
caspase-9 and cleaved PARP was enhanced in LX-1 
cells transfected with pre-miR-29b compared to pre-
miR-control by Western blot (Figure 5C). These findings 
indicate that miR-29b induces cell death and promotes 
subsequent proliferative activity in HSCs.
miR-29b inhibits PIK3R1 and AKT3 by direct 
binding to their 3’-UTR regions
We then searched for the targets of miR-29b by in 
silico searches using two prediction algorithms miRanda 
and TargetScan. We found that the 3’-UTR of PIK3R1, 
AKT3, Col3A1 and Col1A2 contain putative binding 
sites for miR-29b (Figure 6A). To verify whether miR-
29b directly binds to the 3’-UTR of these candidate genes 
and causes translational inhibition, we constructed pMIR-
report plasmids encoding a firefly luciferase transcript with 
either wild-type or mutant 3’-UTR of PIK3R1, AKT3, 
Col1A2 and Col3A1 (Figure 6B). We evaluated their 
respective luciferase reporter activity after co-transfection 
with pre-miR-29b or pre-miR-control in LX-1 cells. The 
results showed that, pre-miR-29b repressed the reporter 
activity of the transcript containing wild-type 3’-UTR of 
PIK3R1 (P < 0.01) and AKT3 (P < 0.01), but not Col1A2 
and Col3A1, compared with pre-miR-control. Whist miR-
133a had no inhibition effect on the reporter activity of 
the mutant 3’-UTR of PIK3R1 and AKT3 (Figure 6B), 
indicating the direct regulation of miR-29b at the 3’-UTR 
Figure 6: miR-29b inhibits liver fibrosis and suppresses the activation of HSCs through direct targeting PIK3R1 and 
AKT3. (A) miR-29b potential binding sites on the 3’-UTR of four candidate genes, PIK3R1, AKT3, Col1A2 and Col3A1. (B) LX1 
cells were transfected with firefly luciferase transcript containing either wild-type or mutant form of 3’-UTR of the 4 candidate genes, in 
the presence of either control or miR-29b precursor, and then assessed for luciferase reporter activity at 48 hours post-transfection. The 
luciferase reporter activity of PIK3R1ang AKT3 was suppressed by wildtype miR-29b. (C) Protein expression of PIK3R1, AKT3 and 
p-AKT3 was reduced by miR-29b in LX1 and in HSC-T6 cells. (D) PIK3R1, AKT3 and p-AKT expressions which were induced in CCl
4
-
treated mice were down-regulated in mice with gene transfer of miR-29b. Values are mean ± SD, *P < 0.01 compared with control mice 




of PIK3R1 and AKT3 transcripts.
To determine whether these findings reflect the 
regulation of endogenous PIK3R1 and AKT3 by miR-
29b, we transiently reintroduced pre-miR-29b into two 
HSC lines LX1 and HSC-T6. Ectopic expression of miR-
29b remarkably reduced protein expression of PIK3R1, 
AKT3 and phosphorylated AKT (p-AKT) in both cell lines 
(Figure 6C), suggesting that PIK3R1 and AKT3 are bona 
fide targets of miR-29b. 
miR-29b inhibits PIK3R1 and AKT3 in liver 
fibrosis in mice 
The effect of miR-29b on protein expression of 
PIK3R1, AKT3 and p-AKT was examined in vivo by 
Western blot. As shown in Figure 6D, protein expression 
of PIK3R1, total AKT3 and p-AKT was significantly 
enhanced in liver fibrotic tissues in CCl
4
-treated mice. In 
contrast, CCl
4
-treated mice supplemented with miR-29b 
showed significant reduced expression of PIK3R1, total 
Figure 7: Knockdown of PIK3R1 or AKT3 reduces HSC activation and induces HSC apoptosis. (A) Knockdown efficiency 
of PIK3R1 or AKT3 in LX1 cell line was confirmed by RT-PCR and (B) by Western blot. (C) Knockdown of PIK3R1 or AKT3 inhibits 
the protein levels of α-SMA and collagen I in LX1 cells by western blot, and (D) by dual-immunofluorescence staining. (E) Knockdown 
of PIK3R1 or AKT3 induced Annexin V positive apoptotic LX1 cells by flow cytometry. Values are mean ± SD from four independent 
experiments in duplicate. (F) Induced apoptosis in LX1 cells by Knockdown of PIK3R1 or AKT3 was confirmed by TUNEL staining. 
Apoptosis index was quantified by counting the proportion of TUNEL-positive cells.
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AKT3 and p-AKT, which paralleled the improvement in 
histological severity of liver fibrosis (Figure 3A). These 
results supported the specific inhibitory effect of miR-
29b on PIK3R1 expression and AKT3 activation in liver 
fibrosis.
Knockdown of PIK3R1 or AKT3 inhibits α-SMA 
and collagen I
To characterize the effect of PIK3R1 or AKT3 on 
liver fibrosis, we knockdown PIK3R1 or AKT3 expression 
in LX1 cells by siRNA transfection. Knockdown 
efficiency was examined by real-time RT-PCR (Figure 
7A) and Western blot (Figure 7B). Knockdown of PIK3R1 
or AKT3 significantly reduced the protein expression of 
α-SMA and collagen I by Western blot (Figure 7C), which 
was further confirmed by immunofluorescence assay 
(Figure 7D).
Knockdown of PIK3R1 or AKT3 induces HSC 
apoptosis
We also examined whether knockdown of PIK3R1 
or AKT3 influences HSC apoptosis. Flow cytometric 
analysis of apoptotic LX1 cells after stained with Annexin 
V/7-AAD showed that knockdown of PIK3R1 or AKT3 
caused significant increase in the number of apoptotic cells 
in LX1, respectively (Figure 7E). This effect was further 
confirmed by TUNEL staining in LX1 cultured slides. 
Knockdown of PIK3R1 or AKT3 displayed more TUNEL 
positive cells compared to control, respectively (Figure 
7F).
DISCUSSION
In this study, we found a significant decrease in 
the expression of miR-29b in human and rodent liver 
fibrotic tissues compared to normal liver tissues. Similar 
down-regulation of miR-29b expression was also 
observed in activated primary HSCs isolated from the 
liver of rodent compared to their quiescent phenotype. 
Downregulation of miR-29 members has been reported 
to be implicated in various fibrotic diseases including 
cardiac fibrosis [17], lung fibrosis [18] and liver fibrosis 
[19]. These data suggested that miR-29b may play a role 
in liver fibrogenesis and its repression may be associated 
with HSCs activation. The mechanism of miR-29b 
downregulation in liver fibrosis is therefore evaluated. 
We found that TGF-β1 down-regulates miR-29b in HSC 
cells, which was associated with a marked upregulation 
of p-Smad3 and α-SMA. The signaling mechanism 
through which TGF-β1 regulates miR-29b expression was 
examined and we revealed that TGF-β1 downregulates 
miR-29b expression through the mechanism of Smad3. 
The interaction of Smad3 with miR-29b came from the 
findings that the conserved Smad3-binding site was found 
in the promoter region of miR-29b and that Smad3 was 
able to interact with the miR-29b promoter region as 
detected by the ChIP-PCR assay (Figure 1G). Thus, miR-
29b is a downstream target gene of Smad3 in liver fibrosis 
that is negatively regulated by TGF-β/Smad3 signaling. 
These findings are consistent with our recent reports in 
pulmonary fibrosis [16] and in renal fibrosis [15] that 
Smad3 mediates TGF-β1-induced downregulation of miR-
29b by binding to miR-29b promoter. 
If miR-29b plays a key part in liver fibrogenesis, 
it would be important to establish that its overexpression 
ameliorated severity of liver fibrosis. To test this, we used 
an ultrasound-microbubble-mediated gene transfer to 
introduce miR-29b into the liver in mice treated with CCl
4. 
We have previously shown that the use of ultrasound-
microbubble-mediated gene transfer is able to effectively 
deliver Dox-inducible miR-29b plasmid into kidney 
to block activation of TGF-β/Smad signaling, thereby 
inhibiting progressive renal fibrosis in rat model [15]. 
In this study, we effectively delivered miR-29b plasmid 
into both normal and disease liver in which higher levels 
of miR-29b transgene were expressed as detected by in 
situ hybridization and by real-time PCR without any side 
effect (Figure 2). In the eight-week CCl
4
-induced liver 
fibrosis model, transduction of miR-29b significantly 
repressed the severity of hepatic fibrosis as evidenced by 
reduced collagen deposition and collagen content (Figure 
3A-3C). We showed that expression of α-SMA, collagen I, 
and TIMP-1 were upregulated in CCl
4
-treated mice. These 
genes are mainly producing by HSCs during fibrogenesis 
[20]. Introduction of miR-29b resulted in significant 
downregulation of α-SMA, collagen I and TIMP-1 
expression, which is more likely the result of reduced 
activation of HSCs. In addition, transduction of miR-29b 
was able to inhibit the activation of Smad3 both in vitro 
and in vivo, an important player in fibrogenic pathway, 
which indicated that miR-29b is not only a downstream 
target of TGF-β/Smad3 in liver fibrogenesis, but also a 
negative feedback-regulator of the TGF-β/Smad3 signaling 
axis in the pathogenesis of liver fibrosis. Therefore, the 
antifibrotic effect of miR-29b in vivo is at least in part due 
to a decreased accumulation of activated matrix producing 
HSCs, reduced collagen production as well as increased 
matrix degradation, thereby blocking fibrosis development 
(Figure 3E). To clarify this hypothesis, an in vitro study on 
cultured HSCs is warranted to determine the direct effect 
by which miR-29b protects against fibrosis. 
To further define the effect of endogenous 
transactivation of miR-29b and to understand the 
functional consequences and molecular basis in liver 
fibrosis, we examined its direct regulation of HSC biology, 
a principal mechanism implicated in the antifibrotic effect 
of miR-29b. We transduced pre-miR-29b in activated 
human (LX-1) and rat (T6) HSCs. In keeping with the 
findings in mice, ectopic expression of miR-29b inhibited 
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the expression of α-SMA, collagen I, TIMP-1 and 
p-Smad3 in both HSC cell lines, suggesting that miR-29b 
negatively regulated fibrosis by targeting the process of 
collagen matrix synthesis through inhibiting the activation 
of HSCs. Moreover, ectopic expression of miR-29b caused 
a growth arrest in both LX-1 and T6 HSCs as evidenced 
by cell viability and colony formation assays. To further 
investigate the mechanism by which miR-29b regulates 
cell growth, we performed FACS; cell cycle distribution 
analysis revealed significantly more miR-29b transfected 
HSCs were arrested in the G1 phase, with a concomitant 
reduction in cellular proliferation compared with miR-
control transfected HSCs. Cell cycle arrest caused by the 
overexpression of miR-29b was associated with induction 
of cyclin D1 and p21cip1 (Figure 4). These findings imply 
that miR-29b reduces liver fibrosis by mechanisms of 
reducing the number of HSCs via causing cell cycle arrest 
and suppressing cell proliferation. 
When liver fibrosis resolves, the activated HSCs 
are either returning to a quiescent state or undergoing 
apoptosis [9,21], which causes a decrease in the number 
of activated HSC. The induction of apoptosis in HSCs 
by miR-29b was also observed concomitantly with the 
inhibition of cellular proliferation, whereby apoptosis 
was executed by the regulation of casepase-9 and PARP 
(Figure 5). Increased expression of miR-29b activated 
caspase-9, triggering the proteolytic cleavage of the 
PARP leading to cellular disassembly and apoptosis. 
Lots of attention has focused on the process of activated 
HSC apoptosis because stimulation of this process in 
vivo promotes accelerated rates of the resolution of liver 
fibrosis [13]. Here we showed that transfection of miR-
29b could significantly increase the susceptibility of HSCs 
to caspase-mediated apoptosis, indicating that apoptosis is 
an additional mechanism of anti-fibrotic effect of miR-29b 
in HSCs [22]. Collectively, our in vitro findings served as 
a direct evidence for the regulatory role of miR-29b in 
HSC activation. 
Having shown that miR-29b is a crucial mediator in 
repressing liver fibrosis through suppressing the activation 
of HSCs, we looked for the possible downstream effectors 
participating in its function. Of note, a single miRNA 
can regulate a multitude of target genes concomitantly. It 
has been reported that miR-29b suppresses progression 
of renal fibrosis by down-regulating tropomyosin 1 and 
COL2A1 [23]. Among the miRNAs predicted to target 
genes, we revealed for the first time that PIK3R1 and 
AKT3 act as critical effectors of miR-29b in liver fibrosis. 
We confirmed the direct interaction of miR-29b in 
negatively regulating PIK3R1 and AKT3 at their 3’-UTR 
regions in HSC cells by luciferase activity assay (Figure 
6A-6B). Moreover, miR-29b dramatically decreased the 
protein expression of PIK3R1, AKT3 and p-AKT3 in 
HSC cells and in fibrotic animal models, indicating the 
translational repression of PIK3R1 and AKT3 by miR-
29b (Figure 6C-6D). Knockdown of PIK3R1 or AKT3 in 
HSCs led to inhibition of α-SMA and collagen I (Figure 
7) and induction of apoptosis. PIK3R1 is a regulatory 
subunit of phosphatidylinositol 3-kinase (PI3K). 
Activation of PI3K is important for HSC proliferation 
in vitro and for hepatic fibrogenesis in rodent induced 
by CCl
4 
[24,25]. PI3K activation leads to the activation 
of its key downstream kinase, AKT, which stimulates 
cell proliferation and inhibits apoptosis in HSCs [26]. 
The PI3K/Akt signaling pathway plays important roles 
in the development and progression of haptic fibrosis 
through regulating extracellular matrix degradation and 
HSC activation [27]. These findings suggest a possible 
mechanism by which miR-29b suppresses liver fibrosis 
through negatively regulates PI3K/AKT signaling 
pathway via direct interaction with PIK3R1 and AKT3. 
This information highlights the potential therapeutic 
mechanism and benefit of miR-29b in inhibiting the PI3K/
AKT pathway to prevent and treat liver fibrosis. 
In conclusion, miR-29b was downregulated in liver 
fibrosis and was negatively regulated by Smad3 in vivo 
and in HSC cells. Importantly, miR-29b was an antifibrotic 
factor and ultrasound-microbubble-mediated miR-29b 
tranduction has prodigious therapeutic potential for liver 
fibrosis by inhibition of collagen production, stimulation 
of matrix degradation and repression the activation of 
HSCs. The molecular mechanisms by which miR-29b 
exerted its antifibrotic function was by directly inhibiting 
PIK3R1 and AKT3, causing inactivation of the PI3K/AKT 
signaling pathway, and ultimately inducting apoptosis of 
activated HSCs. 
MATERIALS AND METHODS
Patients and tissues 
Liver biopsy tissues were obtained from 20 patients 
with liver fibrosis and 13 healthy subjects from Prince of 
Wales Hospital, The Chinese University of Hong Kong, 
and Queen Marry Hospital, The University of Hong Kong, 
Hong Kong. Written consent was obtained prior to sample 
collection, and the study was approved by the Human 
Ethics Committee of The University of Hong Kong and 
The Chinese University of Hong Kong. Tissue biopsies 
were immediately snap-frozen in liquid nitrogen and 
stored at -80°C for later analysis.
Animal models of liver fibrosis 
Liver fibrosis was induced by intraperitoneal (i.p.) 
administration of CCl
4
 (1:1 in olive oil) at a dose of 0.2 
ml/100 g body weight twice-weekly [28,29]. Control 
animals were treated by i.p. injection of olive oil only. 
The animals were sacrificed under anesthesia after 8 
weeks of CCl
4 
treatment. The liver tissues were either 
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snap frozen in liquid nitrogen and stored at -80°C or fixed 
in 10% buffered formalin overnight before embedded 
in paraffin in preparing for histopathological and 
immunohistochemical examinations. Experiments were 
conducted in accordance with principles outlined in the 
Animal Experimentation Ethics Committee Guide for the 
Care and Use of Laboratory Animals, and were approved 
by the Animal Experimentation Ethics Committee of the 
Chinese University of Hong Kong.
Ultrasound-mediated miR-29b transfer in the 
liver 
A mixed solution that contained pTRE2-miR-
29b and Tet-on plasmids/Sonovue (Bracco Diagnostics, 
Princeton, NJ) in the ratio of 1:1 (vol:vol) or the control 
empty vectors (pTRE2-Tet-on/Sonovue) in 200 µl 
[15], was co-transfected into the liver through tail vein 
injection followed by 5 min ultrasound treatment (2W/
cm2) transcutaneously at liver location (THERASONIC 
450, Electro-Medical Supplies, Greenham, England). 
To induce miR-29b transgene expression, Doxycycline 
hyclate (Sigma-Aldrich, St. Louis, MO) was supplied 
in drinking water with a concentration of 200ug/ml 
during the expeiments. As high expression level of miR-
29b was demonstrated to last for 3 weeks after a single 
dose injection in the pilot study, tail vein injection was 
performed at about 2 and half weeks for 3 times in total 
in 8 weeks duration. The numbers of mice in the different 
experimental groups were: Olive oil-treated group, 6; 
CCl
4
-treated group, 8; CCl
4
 and empty vector-treated 






ChIP assay was performed using Transcription 
Factor ChIP kit (Diagenode, Liège, Belgium). LX1 cells 
pretreated with TGF-β1 (10 ng/ml) were cross-linked with 
1% formaldehyde for 10 min at 37°C. The crosslinking 
reaction was stopped by adding glycine and collected 
for nuclei protein extraction. Chromatins from extracted 
crosslinked nuclei were sheared by sonication using 
a Bioruptor (Diagenode, Liège, Belgium) to generate 
200- to 300-bp DNA fragments, and then precipitated 
with antibody for Smad3 (Upstate, Billerica, MA), 
followed by capturing immunoprecipitated proteins/
DNA complex with protein-G-magnetic beads. The 
same amount of non-specific IgG was used as control. 
Precipitated DNAs were amplified by PCR using 
specific primers of the promoter of miR-29b with Smad3 
binding motif: 5’-TGCTTGGAAAGGTGAGGATG-3’ 
and 5’-CCCAACCAAAGGCGGACAGC-3’. The fold 
enrichment was calculated relative to the background 
detected with non-specific IgG using the following 
formula: fold enrichment = 2^ (CT of antibody − CT of 
IgG). 
Dual-luciferase reporter activity assay
The potential miR-29b binding targets were 
predicted by TargetScan (www.targetscan.org) and 
miRanda (www.microRNA.org). Sequence of segments 
with the wild-type or mutant seed region of PIK3R1, 
AKT3, collagen type III alpha 1 (Col3A1) and collagen 
type I alpha 2 (Col1A2) were synthesized and cloned into 
pMIR-REPORT luciferase vector (Ambion, Inc., Grand 
Island, NY) between Hindlll and Spel restriction sites. 
The synthesized oligos were shown in Supplementary 
Table 1. All constructs were verified by sequencing. LX-1 
cells (1×105 cells/well) transiently transfected with pre-
miR-29b (20 nM) or miR-control (20 nM) were seeded 
in 24-well plates. pMIR-REPORT vector (195 ng/well) 
and pRL-TK vector (5 ng/well) were cotransfected using 
lipofectamine 2000 (Invitrogen). Cells were harvested 
48 hours post-transfection and luciferase activities were 
analyzed by the dual-luciferase reporter assay system 
(Promega, Madison, WI).
Immunohistochemistry 
Immunohistochemistry was performed on 
paraffin-embedded liver sections of human normal 
tissues and fibrosis tissues using the specific antibody 
for PIK3R1 (Origene Technologies) or AKT3 (Santa 
Cruz Biotechnology, Santa, Cruz, CA). Negative 
control was replacement of primary antibody with non-
immune serum. The sections were then incubated with 
biotinylated secondary antibodies (1:400) and the avidin-
biotin complex (Histostain - Plus Kits, invitrogen, MD), 
developed with diaminobenzidine tetrahydrochloride 
substrate for 3 min and counterstained with hematoxylin.
Dual-fluorescent immunohistochemistry
Cells grown on sterile slides in 6 well plates were 
fixed with 3% paraformaldehyde and permeated with 0.1% 
Triton X-100. Nonspecific binding was blocked with 1% 
BSA for 30 minutes. The cells were then incubated with 
primary antibodies against PIK3R1 (OriGene, Rockville, 
MD), AKT3 (Santa Cruz), phosphorylated-AKT (Cell 
Signaling, Beverly, MA), α-SMA (Millipore, Billerica, 
MA) and collagen I (SouthernBiotech, Birmingham, 
AL) for 1 hour, followed by secondary antibodies for 30 
minutes. Nuclei were counterstained by 4’,6-diamidino-2-
phenylindole (DAPI) (Invitrogen). Images were captured 
using confocal microscope (Nikon Eclipse TE2000-S).
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RNA interference and transfection 
Human LX1 cells were transfected with siRNA 
against PIK3R1 or siRNA against AKT3, and control 
siRNA-A (Santa Cruze) consisting of a scrambled 
sequence that will not lead to specific degradation of any 
cellular message. The expression vectors were transfected 
into LX1 cells using lipofectamine 2000 (Invitrogen). 
Knockdown efficiency was evaluated by real-time RT-
PCR and Western blot.
Picrosirius red staining for liver collagen and 
image analysis of liver fibrosis 
Liver paraffin sections of 5µm thick were processed 
with 0.1% Picrosirius red for collagen visualization. 
Morphometric analysis was then carried out on a 
computerized image analysis system (Axiocam, Carl Zeiss 
Microscopy, Oberkochen, Germany) and Bioquant Nova 
Prime software (Bioquant Image Analysis Corporation, 
TN). The entire liver section on a slide was capture by 
consecutive fields at a magnification of x100 without 
overlapping. The mean of red color stained area of all 
fields in each section was calculated. The mean area of 
fibrosis in μm2 per field was calculated for each liver 
section [29]. 
Hydroxyproline analysis for collagen content 
To quantify collagen content, hepatic hydroxyproline 
assay was performed (Jiancheng Bioengineering, Nanjing, 
China). Around 80 mg of liver tissues were homogenized 
in ice-cold buffer. The homogenates were incubated 
overnight at 37°C in 5% KOH. The hydrolysates were 
dried by speed vacuum centrifugation over 3~5 h and 
redissolved in a buffer solution. Hydroxyproline levels 
in the hydrolysates were measured at 550 nm. A standard 
curve of samples with known quantities of hydroxyproline 
was generated for each assay [29]. Each sample was 
assayed in triplicate.
HSC culture
Immortalized human HSC cell line (LX-1) (a 
generous gift of Prof. SL Friedman of the Mount Sinai 
School of Medicine, NY) and immortalized rat HSC cell 
line (HSC-T6) (ATCC, Manassas, VA) were used for the 
in vitro experiments. Both LX-1 and HSC-T6 exhibit 
morphologic and functional characteristics of activated 
HSCs. For some experiments, we used primary HSCs 
isolated from male Sprague-Dawley rats. HSCs are 
prepared by collagenase/pronase digestion of rat liver 
using a perfusion system and subsequent fractionation of 
the heterogeneous cell suspension on continuous density 
gradients. Stellate cells are the least dense fraction of the 
nonparenchymal cells, and they float effectively away 
from other hepatic cells during centrifugation. When 
cultured on plastic, freshly isolated hepatic stellate cells 
undergo spontaneous activation. The HSCs maintain 
quiescent at day 2 of culture, and will be fully activated at 
day 7 in culture. The cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM, GIBCO, Grand Island, 
NY) supplemented with 10% fetal bovine serum. 
miR-29b transfection in HSCs 
miR-29b precursor (pre-miR-29b) and the miRNA 
Mimic Negative Control (pre-miR-control) (Ambion Life 
Technologies, Austin, TX) were transiently transfected 
into HSCs (LX-1, HST-T6) using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA) for 48 h and 72 h, respectively. 
Total RNA and protein were isolated from the cell pellets 
to evaluate the transfection efficiency of miR-29b in 
HSCs.
RNA extraction and PCR analyses 
Total RNA was extracted from cell pellets or tissues 
using QIAzol reagent (Qiagen, Hilden, Germany). Semi-
quantitative RT-PCR was performed using Hot-start DNA 
polymerase (Invitrogen) with the housekeeping gene 
β-actin as an internal control. Quantitative real-time PCR 
was performed using SYBR Green master mixture on 
HT7900 system (Applied Biosystems, Foster City, CA). 
The expression level of mature miR-29b was quantified 
by TaqMan microRNA assays (Applied Biosystems). The 
comparative ∆Ct method was used to calculate the relative 
abundance of miRNA compared with RNU6B expression 
(Fold difference relative to RNU6B). 
Western blot
Total protein was extracted from cells pellet. Thirty 
micrograms of protein from each sample were separated 
on 12% SDS-PAGE and transferred onto nitrocellulose 
membranes (GE Healthcare, Piscataway, NJ). Blots were 
immunostained with primary antibody and secondary 
antibody, respectively, with GAPDH served as a loading 
control.
Cell viability assay
After transfection, the LX-1 and HSC-T6 cells were 
digested and re-seeded in 96-well plates (3×103 per well) 
for cell viability assay using the (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt) (MTS) assay (Promega, Madison, 
WI). Twenty uL of reaction solution was added to cultured 
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cells in 100 uL culture medium and incubated at 37°C for 
1.5 h. The optical density was measured at a wavelength 
of 490 nm. The cell viability assay was carried out in four 
wells for three independent experiments.
Colony formation assay 
LX-1 and HSC-T6 cells (5 × 104/well) were plated 
in a 24-well plate and transfected with pre-miR-29b 
or control RNA. After 48 h of transfection, cells were 
collected and seeded (2×103/well) in 6-well plate for 10 to 
14 days. Colonies (≥ 50 cells/colony) were then counted 
after being fixed with 70% ethanol and stained with 5% 
Gentian Violet (ICM Pharma, Singapore, Singapore). 
Cell cycle analysis 
LX1 cells transfected with pre-miR-29b or miR-
control were fixed in 70% ethanol-PBS for 24 hours. 
Cellular DNA was stained with 50 μg/ml propidium iodide 
(BD Pharmingen, Franklin Lakes, NJ), and then sorted by 
FACSCalibur (BD Biosciences, Bedford, MA). Cell-cycle 
profiles were analyzed by ModFit 3.0 software (Becton 
Dickinson, San Diego, CA).
Apoptosis assays 
Apoptosis was determined by dual staining 
with APC Annexin V (BD Biosciences) and 7-amino-
actinomycin (7-AAD) (BD Biosciences) with subsequent 
flow cytometry analysis. The relative proportion of 
Annexin V-positive and 7-AAD negative cells was 
determined using the ModFitLT software (Becton 
Dickinson, San Diego, CA) and counted as early 
apoptotic cells (Annexin V-positive, 7-AAD-negative), 
late apoptotic cells (Annexin V-positive, 7-AAD-positive), 
necrotic cells (Annexin V-negative, 7-AAD-positive) and 
viables (Annexin V-negative, 7-AAD-negative),. 
In addition, terminal deoxynucleotidyl TUNEL 
staining was also employed for detection of apoptosis in 
liver sections (Promega, Madison, WI). The apoptosis 
index was calculated as the percentage of TUNEL-
positive cells which showed clear brown nuclear staining 
(n >1000). 
Statistical analysis 
Data are presented as mean ± SD. Statistical 
analysis was performed using an unpaired Student’s t-test 
for single, or analysis of variance for multiple, group 
comparison. A P value of less than 0.05 was considered 
significant.
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